Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab/trastuzumab (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pertuzumab; Tamoxifen; Trastuzumab; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Pharmacokinetics; Registrational
  • Acronyms FeDeriCa
  • Sponsors Chugai Pharmaceutical; Roche

    • Most Recent Events

    • 25 Sep 2023 According to a Chugai Pharmaceutical media release, company announced Phesgo, a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection, receives manufacturing and marketing approval for HER2-positive breast cancer and colorectal cancer and this approval is based on an international joint phase III clinical trial (FeDeriCa study) and (PHranceSCa study).
    • 03 Sep 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 13 Jun 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top